Overview

Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids

Status:
Not yet recruiting

Trial end date:
2026-05-30

Target enrollment:

Participant gender:

Summary

From patients with intermediate risk non-muscle invasive bladder cancer tumor (NMIBC) specimens will be harvested during transurethral resection. Fresh specimens will be cultured as patient derived organoids (PDO). After approx. 10 days, PDO are exposed to different drugs that are used as intravesical instillation agents in these patients (epirubicin, mitomycin, gemcitabine, docetaxel). After 2 days of exposure, PDO viability will be measured. The drug with the highest antitumor effect on PDO will be applied as weekly intravesical instillations 6 times. Thereafter, patients are followed according to the standard of care.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital Inselspital, Berne

Collaborators:

Hospital Centre Biel/Bienne
University of Bern

Treatments:

Docetaxel
Epirubicin
Gemcitabine
Mitomycin
Mitomycins